LAG3 and cancer: Finally, our findings are consistent with the notion that the addition of LAG-3 blockade to PD-1 blockade could enhance the activity of tumor-reactive yet dysfunctional CD8 memory T cells in the TME, but our findings do not preclude a potential role for combination blockade in also augmenting T cell priming in the context of cancer (62).